Rhinitus/Sinusitis/Ocular Allergy News

The FDA approved olopatadine hydrochloride and mometasone furoate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis in adults and children aged 12 years and older, according to a press release.

Laxative exposure early in life was associated with later allergic disease development, including rhinitis, atopic dermatitis and asthma, according to a cohort study published in Annals of Allergy, Asthma & Immunology.

Allergy and asthma treatment improved this year as the FDA approved multiple medications for new treatment. Here are the top developments for 2021 as reported by Healio.

COVID-19 dominated 2021, as patients and providers balanced its treatment and prevention against their allergy and asthma needs.

Most individuals with onset of allergic sensitization when aged 8 years or younger developed asthma or rhinitis before young adulthood, according to data published in The Journal of Allergy and Clinical Immunology: In Practice.

People with hay fever, rhinitis, atopic eczema and other allergic conditions had a lower risk for developing COVID-19, particularly if they also had asthma, according to a study published in Thorax.

Patients with nasal polyps often have a slow, frustrating path to therapy. Symptoms initially manifest as congestion or a runny nose, which may be attributed to allergies and treated with over-the-counter medications.

African American patients with chronic rhinosinusitis had worse sleep quality even after treatment compared with their white counterparts, according to results of a prospective cohort study.

Dupilumab and benralizumab both improved sense of smell in patients with chronic rhinosinusitis with nasal polyps, and benralizumab also decreased nasal blockage, according to results of two studies.

Treating patients with allergy-like symptoms can be difficult during the pandemic, especially when patients show signs that resemble COVID-19.